Related Experiment Videos

Effects of defibrotide on peripheral obliterative vascular diseases

Haemostasis
|January 1, 1986
PubMed

Insights

Defibrotide therapy improved blood flow and reduced pain in patients with vascular disorders like atherosclerotic obliterative vascular disorder and Buerger

Area of Science:

  • Vascular Medicine
  • Pharmacology

Background:

  • Atherosclerotic obliterative vascular disorder and Buerger's disease cause significant pain and reduced mobility.
  • Effective treatments for these conditions are crucial for improving patient quality of life.

Purpose of the Study:

  • To evaluate the efficacy of defibrotide in patients with atherosclerotic obliterative vascular disorder and Buerger's disease.
  • To assess the impact of defibrotide on pain, vascular function, and blood flow.

Main Methods:

  • A study involving 29 patients with atherosclerotic obliterative vascular disorder and 9 with Buerger's disease.
  • Treatment with 600 mg defibrotide daily for 10 days, followed by thrice-weekly for 3 months.
  • Evaluation using hemostatic parameters, venostasis (cuff) test, treadmill testing, and radionuclide arteriography.

Main Results:

  • Patients experienced increased pain-free intervals in daily life and during treadmill tests.
  • Significant improvements were observed in the cuff test results.
  • Radionuclide arteriography indicated enhanced blood perfusion.

Conclusions:

  • Defibrotide therapy shows promise in improving clinical outcomes for patients with atherosclerotic obliterative vascular disorder and Buerger's disease.
  • The drug positively impacts pain reduction, vascular function, and blood flow in these patient populations.

Related Concept Videos